WallStSmart
SYK

Stryker Corporation

NYSE: SYK · HEALTHCARE · MEDICAL DEVICES

$315.13
+0.00% today

Updated 2026-04-29

Market cap
$125.43B
P/E ratio
39.08
P/S ratio
4.99x
EPS (TTM)
$8.38
Dividend yield
1.03%
52W range
$319 – $402
Volume
2.0M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Stryker Corporation (SYK) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$315.13
Consensus
$429.42
+36.27%
2030 Target
$1,160.39
+268.23%
DCF
$263.22
-19.72% MoS
12 analysts:
5 Buy3 Hold0 Sell

Management guidance

No specific revenue targets or forward guidance from management provided in available data. CEO guidance is absent from research materials; relying on analyst consensus and historical growth trajectory of 11.8% 5Y CAGR.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$1,922.93
$36.9B Rev × 20x P/S
Base case (2030)
$1,160.39
$36.9B Rev × 12x P/S
Bear case (2030)
$762.54
$36.9B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$20.5B$22.6B$25.1B$27.6B$29.9B$32.3B$34.6B$36.9B
Revenue growth—10.2%11.2%9.9%8.4%7.9%7.1%6.7%
EPS$10.60$12.19$13.63$15.12$16.92$18.65$20.10$21.58
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$862.00$928.31$1,027.77$1,094.08$1,160.39

Catalysts & risks

Growth catalysts
+ Q1 2026 earnings report (April 30, 2026) - critical test of Mako RPS surgical robotics and orthopedic innovation adoption
+ Full operational recovery post-cyberattack (completed by early April 2026) - demonstrates business resilience and rapid restoration
+ Mako Robotic Power System limited release and adoption acceleration - next-gen surgical robotics driving premium pricing and procedure growth
+ SmartHospital Platform expansion - digital healthcare ecosystem driving recurring revenue and customer lock-in
+ Continued orthopedic innovation pipeline launches (T2 Alpha Humerus, Synchfix EVT) - market share gains in trauma and joint fixation
Key risks
- Cyberattack recovery incomplete or data breach litigation material impact - 50TB data stolen, 6+ lawsuits filed, potential IP/competitive exposure
- Mako RPS adoption slower than expected - capital equipment sales dependent on surgeon adoption and hospital capital budgets
- Reimbursement pressure on orthopedic and surgical robotics procedures - healthcare cost containment by payers/CMS
- Integration and execution risk from recent leadership changes (new VP Investor Relations, CFO transition)
- Macro uncertainty - hospital procedure volumes sensitive to economic cycles, elective surgery deferral, geopolitical tensions (Iran-linked cyberattack attribution)

Methodology

Stryker Corporation's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 12 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.